Background Dual-targeted anti-HER2 therapy significantly improves outcomes in HER2-
positive breast cancer and could be beneficial in other HER2-positive cancers. JACOB's end …

Introduction: Despite significant improvements in systemic chemotherapy over the last two
decades, the prognosis of patients with advanced disease remains dismal. Collaborative …

Gastroesophageal (GE) adenocarcinomas are highly lethal malignancies and despite
multiple chemotherapy options, 5-year survival rates remain dismal. Chemotherapy is the …

Trastuzumab in combination with capecitabine or 5-fluorouracil and cisplatin has been
approved by the European Medicines Agency (EMEA) for the treatment of patients with …

Background Trastuzumab, a monoclonal antibody against human epidermal growth factor
receptor 2 (HER2; also known as ERBB2), was investigated in combination with …

Molecularly targeted therapeutic agents are constantly being developed and have been
shown to be effective in various clinical trials. One group of representative targeted …

Aim: Patients with advanced gastric cancer have a relatively poor prognosis with few
therapeutic alternatives beyond first-line therapy. The purpose of this manuscript is to …

Introduction: In metastatic gastric cancer, chemotherapy is the standard treatment because it
prolongs survival when compared to best supportive care alone. However, even after the …

Patients with advanced-stage hepatocellular carcinomas (HCCs) have several options for
systemic therapy; however, these agents are generally less effective in those with high-risk …

Gastric cancer is the fifth most common cancer worldwide, and the treatment of advanced
gastric cancer has relatively little progress. With the continuous development of molecularly …